TW201107345A - Immunoglobulins - Google Patents

Immunoglobulins Download PDF

Info

Publication number
TW201107345A
TW201107345A TW099116859A TW99116859A TW201107345A TW 201107345 A TW201107345 A TW 201107345A TW 099116859 A TW099116859 A TW 099116859A TW 99116859 A TW99116859 A TW 99116859A TW 201107345 A TW201107345 A TW 201107345A
Authority
TW
Taiwan
Prior art keywords
seq
antigen binding
heavy chain
binding protein
antibody
Prior art date
Application number
TW099116859A
Other languages
English (en)
Chinese (zh)
Inventor
Claire Ashman
Jonathan Henry Ellis
Paul Andrew Hamblin
Alan Peter Lewis
Martin Anibal Orecchia
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of TW201107345A publication Critical patent/TW201107345A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW099116859A 2009-05-28 2010-05-26 Immunoglobulins TW201107345A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18183309P 2009-05-28 2009-05-28
US28893009P 2009-12-22 2009-12-22

Publications (1)

Publication Number Publication Date
TW201107345A true TW201107345A (en) 2011-03-01

Family

ID=42335086

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099116859A TW201107345A (en) 2009-05-28 2010-05-26 Immunoglobulins

Country Status (21)

Country Link
US (2) US8680245B2 (enExample)
EP (1) EP2435481A1 (enExample)
JP (1) JP5919188B2 (enExample)
KR (1) KR20120034679A (enExample)
CN (1) CN102459341A (enExample)
AR (1) AR078047A1 (enExample)
AU (1) AU2010251955A1 (enExample)
BR (1) BRPI1016061A2 (enExample)
CA (1) CA2763443A1 (enExample)
CO (1) CO6400150A2 (enExample)
CR (1) CR20110664A (enExample)
DO (1) DOP2011000347A (enExample)
EA (1) EA201190275A1 (enExample)
IL (1) IL216261A0 (enExample)
MA (1) MA33381B1 (enExample)
MX (1) MX2011012622A (enExample)
PE (1) PE20120401A1 (enExample)
SG (1) SG176203A1 (enExample)
TW (1) TW201107345A (enExample)
UY (1) UY32664A (enExample)
WO (1) WO2010136481A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
ATE509033T1 (de) 2006-03-20 2011-05-15 Univ California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
JP5906090B2 (ja) 2009-02-17 2016-04-20 コーネル・リサーチ・ファンデーション・インコーポレイテッドＣｏｒｎｅｌｌ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ， Ｉｎｃｏｒｐｏｒａｔｅｄ 癌の診断のための方法およびキットならびに治療価の推定
PE20120401A1 (es) 2009-05-28 2012-05-04 Glaxo Group Ltd Proteina de enlace de il-13
CA3040276A1 (en) 2009-12-02 2011-06-09 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
CA3215087A1 (en) * 2013-01-03 2014-07-10 Meso Scale Technologies, Llc Assay panels
EP2981286A4 (en) * 2013-04-05 2016-08-24 Hoffmann La Roche ANTI-IL-4 ANTIBODIES AND BISPECIFIC ANTIBODIES AND USES THEREOF
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
LT3248986T (lt) * 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
WO2015200905A2 (en) * 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
WO2016054114A1 (en) * 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
CN108136012B (zh) 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
JP7044700B2 (ja) * 2015-10-02 2022-03-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
TW202228789A (zh) * 2020-10-15 2022-08-01 美商建南德克公司 用於長效遞送治療劑之多能蛋白聚醣（ｖｇ１）的玻尿酸結合衍生物
CN118005784A (zh) * 2022-11-08 2024-05-10 上海洛启生物医药技术有限公司 抗il-13长效纳米抗体序列及其应用
WO2026114819A1 (en) * 2024-11-26 2026-06-04 Glaxosmithkline Intellectual Property Development Limited Il-13 antigen binding proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
WO2003092610A2 (en) 2002-05-01 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat hiv infection and aids
GB0414799D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Immunoglobulins
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0600488D0 (en) 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
BRPI0710572A2 (pt) * 2006-01-24 2013-01-08 Domantis Limited ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
NZ601815A (en) 2008-03-31 2014-10-31 Genentech Inc Compositions and methods for treating and diagnosing asthma
PE20120401A1 (es) 2009-05-28 2012-05-04 Glaxo Group Ltd Proteina de enlace de il-13

Also Published As

Publication number Publication date
CA2763443A1 (en) 2010-12-02
JP2012528110A (ja) 2012-11-12
DOP2011000347A (es) 2012-01-15
PE20120401A1 (es) 2012-05-04
AU2010251955A1 (en) 2011-12-22
CN102459341A (zh) 2012-05-16
KR20120034679A (ko) 2012-04-12
WO2010136481A1 (en) 2010-12-02
JP5919188B2 (ja) 2016-05-18
SG176203A1 (en) 2011-12-29
US20100303821A1 (en) 2010-12-02
US20120082682A1 (en) 2012-04-05
US8680245B2 (en) 2014-03-25
UY32664A (es) 2010-12-31
AR078047A1 (es) 2011-10-12
CO6400150A2 (es) 2012-03-15
CR20110664A (es) 2012-02-27
EA201190275A1 (ru) 2012-11-30
EP2435481A1 (en) 2012-04-04
IL216261A0 (en) 2012-01-31
MA33381B1 (fr) 2012-06-01
MX2011012622A (es) 2011-12-14
BRPI1016061A2 (pt) 2016-09-13

Similar Documents

Publication Publication Date Title
JP5919188B2 (ja) Ｉｌ−１３結合タンパク質
RU2746926C2 (ru) Антагонистические антитела, которые связываются с человеческими TGFβ1, TGFβ2 и TGFβ3, и их применение при лечении фиброза легких
CN114502595B (zh) 针对脊髓灰质炎病毒受体(pvr)的抗体及其用途
AU2017230091B2 (en) Activin type 2 receptor binding proteins and uses thereof
TW200944231A (en) Antigen-binding constructs
JP2023515260A (ja) 抗ヒトインターロイキン－４受容体α抗体及びその調製方法並びに使用
KR20180099723A (ko) 항-tl1a/항-tnf-알파 이중특이적 항원 결합 단백질 및 그의 용도
TWI815305B (zh) Pd-1/vegf四價雙特異性抗體、其製備方法和用途
KR20210049792A (ko) 인간 il-4r 결합 항체, 이의 항원 결합 단편, 및 이의 의학적 용도
KR20190029641A (ko) 항-pd-1 항체, 이의 생산 방법 및 사용 방법
CN107406508A (zh) 人源化的抗trop‑2单克隆抗体及其应用
TW200918554A (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
CN110845618A (zh) 双特异性t细胞活化抗原结合分子
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
KR20160019434A (ko) 항-tweakr 항체 및 그의 용도
KR20230017841A (ko) Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
JP7163275B2 (ja) 抗－ｉｌ－２２ｒ抗体
RU2770620C1 (ru) Связывающие молекулы, вызывающие клеточную активацию
TW202229340A (zh) 多特異性抗體及抗體組合
JP2025026488A (ja) ヒトプログラム細胞死受容体ｐｄ－１に対する抗体
TW202415677A (zh) 抗TNFα抗體及組合物
JP2025503707A (ja) ガレクチン－１０抗体
TW202530256A (zh) 多特異性抗原結合多肽之組合物及使用方法
TW202607036A (zh) 多特異性結合劑及其用途
HK40073145A (en) Antibodies against the poliovirus receptor (pvr) and uses thereof